Immedica wins FDA accelerated approval for Loargys, aids 250 Americans

Immedica Pharma secured accelerated approval from the U.S. Food and Drug Administration for Loargys (pegzilarginase‑nbln) on Feb. 23, 2026, clearing the first U.S. indication for treatment of hyperargininemia in patients aged 2 years and older with Arginase 1 Deficiency, a disorder that the company estimates affects about 250 people in the United States.

The approval, announced by Immedica in a PR Newswire release, was granted under the FDA’s accelerated approval pathway and is conditioned on co‑treatment with dietary protein restriction. Regulators based the decision on a surrogate endpoint: reduction of plasma arginine. Immedica noted that continued approval “may be contingent upon verification and description of clinical benefit in a confirmatory trial.”

Loargys is described by the company as “a novel, recombinant, human arginase‑1 enzyme that has been shown to rapidly and sustainably lower levels of the amino acid arginine and its toxic metabolites in plasma, making it the first and only therapy proven to lower plasma arginine.” The therapy is expected to be administered weekly, either infused or injected, and Immedica says it expects to make Loargys available in the U.S. in April.

Clinicians and patient advocates said the mechanism marks a shift from symptom management to addressing the underlying enzyme deficiency. Stephen Cederbaum, M.D., professor of human and medical genetics at UCLA, said, “The accelerated approval of Loargys offers a fundamentally new approach that addresses the enzyme deficiency itself. Since persistently elevated arginine and its metabolites have been reported to be the proximal or direct driver of disease progression, this is a major advancement in metabolic medicine.”

Immedica framed the decision as a milestone for families and the rare disease community. Anders Edvell, the company’s chief executive, said, “Today’s FDA accelerated approval of Loargys is an important milestone for Immedica and for patients and families affected by Arginase 1 Deficiency in the U.S. … This outcome is the result of collaborative efforts across the entire ARG1‑D community including patients, advocacy groups, researchers, and clinicians. We are proud to be able to deliver a treatment option for patients and families who have long awaited progress.”

The approval follows a rocky regulatory history for the compound. FiercePharma reported that four years earlier the FDA had issued “its most heavy‑handed form of a rejection” to a prior company behind pegzilarginase, and that an August complete response letter had suggested accelerated approval would be possible only with postmarketing trials designed to validate surrogate endpoints and demonstrate clinical benefit. Immedica earned European Medicines Agency authorization for Loargys in December 2023.

Public health and equity questions now move to the fore. Accelerated approval gives patients earlier access to a targeted therapy for an ultra‑rare, devastating condition, often diagnosed in late infancy or early childhood and associated with spasticity, seizures and intellectual disability, but it also leaves critical uncertainties: confirmatory trial design and timelines, long‑term safety data, the specifics of labeled pediatric dosing, and practical access barriers such as infusion infrastructure, insurance coverage and out‑of‑pocket cost.

Immedica’s press materials included an “IMPORTANT SAFETY INFORMATION” header but did not publish full safety text in the release. Regulators, clinicians and patient groups will be watching the company’s planned confirmatory trials and commercial rollout closely to ensure that the small community of people with ARG1‑D can obtain timely, affordable and safe access to the new therapy.